Huge congratulations on the new release, Yu-Jung Chen and team! ☺️ Check it out in nature: go.nature.com/3V8Hsjt 📰 Read the PR: bit.ly/3Z5lkYm

Saying ‘I don’t know’ in talks has become a lost art, unfortunately. Super interesting discussions require us to be open about what we don’t know and what still needs to be explored. Here’s my recipe for answering questions in talks:

New Night Science Podcast episode! Michael Fischbach talks about choosing a research problem, managing risks, and turning crises into opportunities; as discussed in his Cell paper "Problem choice and decision trees in science and engineering" Michael Fischbach buzzsprout.com/1744020/episod…

I’m excited to share new work out of the lab in Nature Metabolism today on the impact of tumor-relevant glucose concentrations on the response to pyrimidine synthesis inhibitors. nature.com/articles/s4225…. PDF: rdcu.be/d1vkV

So excited to share our new paper out in nature led by the fabulous Anais Elewaut and Guillem Estivill providing mechanistic insights into anti-tumor immunity and why it may fail in so many patients! Sky-torial on Anna Obenauf.bsky.social rdcu.be/d1F7s

So happy to see this work out! A little of a comcamaraderie feel with Xueqian Zhuang as we are right next to each other's lab, presented our work together in symposium and finalized our manuscript in Nature at around the same time. I love this work and congrats Tuomas Tammela!

Amazing work and breakthrough in the field of ecDNA cancer biology. This is a work I greatly admired as it is paradigm shifting in modeling tumors that fits the real world picture. Congratulations on this amazing work Andrea Ventura !

Published yesterday (Feb 27, 2025), a groundbreaking case study by Georgiana Long et al. may redefine GBM immunotherapy. The team reports the first known instance of upfront neoadjuvant administration of immune checkpoint inhibitors (a-PD-1 + a-CTLA-4 + a-LAG3) before surgery in